GS 2121
Alternative Names: GS-2121Latest Information Update: 03 Oct 2024
At a glance
- Originator Gilead Sciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Aug 2024 Preclinical trials in Solid tumours in USA (PO) before August 2024 (NCT06532565)
- 01 Aug 2024 Gilead Sciences plans a phase I trial for Solid tumours (Late-stage disease, combination therapy, Monotherapy, Second-line tehrapy or greater) in August 2024 (PO) (NCT06532565) (EUCT2024-511739-81)
- 26 Jul 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06532565)